Literature DB >> 24954001

Oxidized alginate hydrogels for bone morphogenetic protein-2 delivery in long bone defects.

Lauren B Priddy1, Ovijit Chaudhuri2, Hazel Y Stevens3, Laxminarayanan Krishnan4, Brent A Uhrig5, Nick J Willett5, Robert E Guldberg6.   

Abstract

Autograft treatment of large bone defects and fracture non-unions is complicated by limited tissue availability and donor site morbidity. Polymeric biomaterials such as alginate hydrogels provide an attractive tissue engineering alternative due to their biocompatibility, injectability, and tunable degradation rates. Irradiated RGD-alginate hydrogels have been used to deliver proteins such as bone morphogenetic protein-2 (BMP-2), to promote bone regeneration and restoration of function in a critically sized rat femoral defect model. However, slow degradation of irradiated alginate hydrogels may impede integration and remodeling of the regenerated bone to its native architecture. Oxidation of alginate has been used to promote degradation of alginate matrices. The objective of this study was to evaluate the effects of alginate oxidation on BMP-2 release and bone regeneration. We hypothesized that oxidized-irradiated alginate hydrogels would elicit an accelerated release of BMP-2, but degrade faster in vivo, facilitating the formation of higher quality, more mature bone compared to irradiated alginate. Indeed, oxidation of irradiated alginate did accelerate in vitro BMP-2 release. Notably, the BMP-2 retained within both constructs was bioactive at 26days, as observed by induction of alkaline phosphatase activity and positive Alizarin Red S staining of MC3T3-E1 cells. From the in vivo study, robust bone regeneration was observed in both groups through 12weeks by radiography, micro-computed tomography analyses, and biomechanical testing. Bone mineral density was significantly greater for the oxidized-irradiated alginate group at 8weeks. Histological analyses of bone defects revealed enhanced degradation of oxidized-irradiated alginate and suggested the presence of more mature bone after 12weeks of healing.
Copyright © 2014 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Alginate; BMP-2 (bone morphogenetic protein-2); Bioactivity; Bone regeneration; Oxidation

Mesh:

Substances:

Year:  2014        PMID: 24954001      PMCID: PMC4160396          DOI: 10.1016/j.actbio.2014.06.015

Source DB:  PubMed          Journal:  Acta Biomater        ISSN: 1742-7061            Impact factor:   8.947


  41 in total

Review 1.  Delivering on the promise of bone morphogenetic proteins.

Authors:  R H Li; J M Wozney
Journal:  Trends Biotechnol       Date:  2001-07       Impact factor: 19.536

Review 2.  Bone graft substitutes.

Authors:  Cato Laurencin; Yusuf Khan; Saadiq F El-Amin
Journal:  Expert Rev Med Devices       Date:  2006-01       Impact factor: 3.166

3.  Spatiotemporal control of vascular endothelial growth factor delivery from injectable hydrogels enhances angiogenesis.

Authors:  E A Silva; D J Mooney
Journal:  J Thromb Haemost       Date:  2007-01-09       Impact factor: 5.824

4.  Quantitative assessment of scaffold and growth factor-mediated repair of critically sized bone defects.

Authors:  Megan E Oest; Kenneth M Dupont; Hyun-Joon Kong; David J Mooney; Robert E Guldberg
Journal:  J Orthop Res       Date:  2007-07       Impact factor: 3.494

Review 5.  Growth factors and bone regeneration: how much bone can we expect?

Authors:  Aaron Nauth; Bill Ristevski; Ru Li; Emil H Schemitsch
Journal:  Injury       Date:  2011-04-13       Impact factor: 2.586

6.  Hyaluronic acid hydrogels with controlled degradation properties for oriented bone regeneration.

Authors:  Jennifer Patterson; Ruth Siew; Susan W Herring; Angela S P Lin; Robert Guldberg; Patrick S Stayton
Journal:  Biomaterials       Date:  2010-06-23       Impact factor: 12.479

7.  Bone: formation by autoinduction.

Authors:  M R Urist
Journal:  Science       Date:  1965-11-12       Impact factor: 47.728

8.  Adverse effects associated with high-dose recombinant human bone morphogenetic protein-2 use in anterior cervical spine fusion.

Authors:  Lisa B E Shields; George H Raque; Steven D Glassman; Mitchell Campbell; Todd Vitaz; John Harpring; Christopher B Shields
Journal:  Spine (Phila Pa 1976)       Date:  2006-03-01       Impact factor: 3.468

9.  Spatiotemporal delivery of bone morphogenetic protein enhances functional repair of segmental bone defects.

Authors:  Yash M Kolambkar; Joel D Boerckel; Kenneth M Dupont; Mehmet Bajin; Nathaniel Huebsch; David J Mooney; Dietmar W Hutmacher; Robert E Guldberg
Journal:  Bone       Date:  2011-05-18       Impact factor: 4.398

10.  Dual growth factor delivery and controlled scaffold degradation enhance in vivo bone formation by transplanted bone marrow stromal cells.

Authors:  Craig A Simmons; Eben Alsberg; Susan Hsiong; Woo J Kim; David J Mooney
Journal:  Bone       Date:  2004-08       Impact factor: 4.398

View more
  20 in total

Review 1.  MiRNA inhibition in tissue engineering and regenerative medicine.

Authors:  Kelsey R Beavers; Christopher E Nelson; Craig L Duvall
Journal:  Adv Drug Deliv Rev       Date:  2014-12-29       Impact factor: 15.470

Review 2.  Functional augmentation of naturally-derived materials for tissue regeneration.

Authors:  Ashley B Allen; Lauren B Priddy; Mon-Tzu A Li; Robert E Guldberg
Journal:  Ann Biomed Eng       Date:  2014-11-25       Impact factor: 3.934

3.  A bioactive synthetic membrane improves bone healing in a preclinical nonunion model.

Authors:  Malcolm R DeBaun; Brett P Salazar; Yan Bai; Michael J Gardner; Yunzhi Peter Yang; Chi-Chun Pan; Alex Martin Stahl; Seydesina Moeinzadeh; Sungwoo Kim; Elaine Lui; Carolyn Kim; Sien Lin; L Henry Goodnough; Harsh Wadhwa
Journal:  Injury       Date:  2022-01-15       Impact factor: 2.586

Review 4.  Segmental long bone regeneration guided by degradable synthetic polymeric scaffolds.

Authors:  Xiaowen Xu; Jie Song
Journal:  Biomater Transl       Date:  2020-12-28

5.  Amniotic membrane attenuates heterotopic ossification following high-dose bone morphogenetic protein-2 treatment of segmental bone defects.

Authors:  Lauren B Priddy; Laxminarayanan Krishnan; Marian H Hettiaratchi; Sukhita Karthikeyakannan; Nikhil Gupte; Robert E Guldberg
Journal:  J Orthop Res       Date:  2022-03-27       Impact factor: 3.102

Review 6.  Polysaccharide-Based Controlled Release Systems for Therapeutics Delivery and Tissue Engineering: From Bench to Bedside.

Authors:  Tianxin Miao; Junqing Wang; Yun Zeng; Gang Liu; Xiaoyuan Chen
Journal:  Adv Sci (Weinh)       Date:  2018-01-08       Impact factor: 16.806

Review 7.  Therapeutics and delivery vehicles for local treatment of osteomyelitis.

Authors:  Leah H Cobb; Emily M McCabe; Lauren B Priddy
Journal:  J Orthop Res       Date:  2020-04-21       Impact factor: 3.494

8.  Hydrogel-based Delivery of rhBMP-2 Improves Healing of Large Bone Defects Compared With Autograft.

Authors:  Laxminarayanan Krishnan; Lauren B Priddy; Camden Esancy; Mon-Tzu Alice Li; Hazel Y Stevens; Xi Jiang; Lisa Tran; David W Rowe; Robert E Guldberg
Journal:  Clin Orthop Relat Res       Date:  2015-09       Impact factor: 4.176

9.  Delivery vehicle effects on bone regeneration and heterotopic ossification induced by high dose BMP-2.

Authors:  Laxminarayanan Krishnan; Lauren B Priddy; Camden Esancy; Brett S Klosterhoff; Hazel Y Stevens; Lisa Tran; Robert E Guldberg
Journal:  Acta Biomater       Date:  2016-12-08       Impact factor: 8.947

10.  [Study on the gelatin methacryloyl composite scaffold with exogenous transforming growth factor β 1 to promote the repair of skull defects].

Authors:  Xiangyu Liu; Zhaodong Wang; Chen Xu; Jianzhong Guan; Bangguo Wei; Yajun Liu
Journal:  Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi       Date:  2021-07-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.